Non-Hodgkin lymphoma (NHL) as a second neoplasm occurring after neuroblastoma treatment

Siegert, E.; Weissbach, G; Fischer, Rainer; Lauterbach, I.

doi:10.1002/(sici)1096-911x(199801)30:1<18::aid-mpo7>3.0.co;2-3

Cited by 7 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second malignancies after neuroblastoma described up to now included thyroid tumor, osteogenic sarcoma, soft tissue sarcoma, acute myeloid and lymphoid leukemias and brain tumor 1, 3, 5, 6, 7, 8, 9, 10, 18, 19, 20, 21, 22. One case of dermatofibrosarcoma and one secondary non‐Hodgkin lymphoma (NHL) have also been reported 23, 24. Among the 12 SMN following neuroblastoma in our study, thyroid and breast cancers were the most frequent observed SMN types.…”

Section: Discussionsupporting

confidence: 53%

Long‐term risk of second malignant neoplasms after neuroblastoma in childhood: Role of treatment

Rubino

Adjadj

Guérin

et al. 2003

Intl Journal of Cancer

View full text Add to dashboard Cite

The aim of our study was to quantify the risk of second malignant neoplasms (SMNs) among long-term survivors of neuroblastoma and to study the influence of treatment on this risk. We studied data from 544 5-year survival patients diagnosed with neuroblastoma before age 16 years at 8 French and British treatment centres from 1948 to 1986. After an average follow-up of 15 years (range, 5-38 years), 12 children developed a total of 13 SMNs, whereas 1.19 were expected from general population rates. Among these SMNs, there were 5 thyroid and 3 breast cancers. Increases of the risks of SMN were observed with time since neuroblastoma diagnosis and attained age. In a multivariate analysis, the relative risk of SMN associated with radiotherapy was 4.3 (95% CI 0.8 -78), whereas no increased risk of SMN was associated with the administration of chemotherapy as a whole (RR ‫؍‬ 0.4, 95% CI 0.1-1.9). Young children treated for a neuroblastoma have significantly increased risks of SMN over 3 decades of follow-up. Radiotherapy treatment was found to be an important risk factor for developing SMNs, whereas no effect of chemotherapy was evidenced. Although our findings reflect the late effects of past therapeutic modalities, they underscore the importance of long-term surveillance of young children treated for a neuroblastoma. For these patients, many more years of follow-up are required to appreciate their overall risks of treatment-related SMNs. © 2003 Wiley-Liss, Inc. Key words: second malignant neoplasm; radiation; childhood cancer; neuroblastomaNeuroblastoma is one of the most common solid tumors in childhood. Conventional treatments of this neoplasm integrate surgery, radiation therapy, combination chemotherapy and more recently, high-dose chemotherapy followed by bone marrow transplantation. Treatment options are related to age of the child, location and biology of the tumor and stage of disease.After successful treatment of malignant diseases in childhood, the problem of long-term complications came to the fore. General evaluation of the long-term carcinogenic risks induced by radiotherapy, chemotherapy and their association after treatment for childhood cancer, have already been published. 1-5 However, cohort studies dealing with the very long-term incidence of second malignant neoplams (SMNs) in children initially treated for a neuroblastoma are sparse. 1,3,[5][6][7][8][9][10] This rarity is due in part to the low survival rates from neuroblastoma, in particular for the patients treated in past decades before the introduction of new therapeutic approaches. Therefore, little is known about the factors that determine the long-term risk of SMN following this cancer.In our current study, we investigated the role of radiotherapy and chemotherapy given for the neuroblastoma treatment on the risk of subsequent SMN development for 544 5-year survival patients treated for a neuroblastoma from 1948 -1986 at 8 hospital centres in France and Great Britain. Our study, including about 1/3 of 25-year survival patients, enabled us to a...

show abstract

Section: Discussionsupporting

confidence: 53%

Long‐term risk of second malignant neoplasms after neuroblastoma in childhood: Role of treatment

Rubino

Adjadj

Guérin

et al. 2003

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Because data on drug use were gathered prior to disease onset, and because little is known about drug-associated non-Hodgkin's lymphoma, it is unlikely that information bias invalidated our results. Hospitalizations for conditions that have been associated with non-Hodgkin's lymphoma were combined in a summary indicator, and number of days of follow-up was adjusted for in the analysis (4,5,9,13,(34)(35)(36). Study limitations included no available data on other risk factors or risk indicators such as lifestyle, smoking, body mass index, nutrition, or occupation that might have confounded our results (14,16,34,(37)(38)(39)(40)(41)(42).…”

Section: Discussionmentioning

confidence: 99%

Prescription Medications Associated with a Decreased Risk of Non-Hodgkin's Lymphoma

Beiderbeck

Holly²,

Sturkenboom³

et al. 2003

American Journal of Epidemiology

View full text Add to dashboard Cite

Earlier epidemiologic studies have suggested an inverse association between non-Hodgkin's lymphoma and exposure to histamine(2) (H(2)) blockers, nonsteroidal anti-inflammatory drugs, cholesterol-lowering drugs, and antibiotics. Data from the PHARMO database were used to conduct a nested, population-based case-control study that included 1985-1998 drug-dispensing records for 300,000 residents of six Dutch cities. Included were those subjects without a previous history of cancer who were aged >/=20 years and were registered with an incident primary discharge diagnosis of non-Hodgkin's lymphoma between 1991 and 1998. This paper includes data on 211 cases and 800 controls individually matched on sex, age, community pharmacy, calendar time, and duration of follow-up. Conditional logistic regression analysis was used to evaluate the association between non-Hodgkin's lymphoma and categories of cumulative drug use in days. In multivariate analyses, nonsignificant risk reductions were found for all drugs tested, and the negative association tended to increase with increasing duration of use. For women, the odds ratio for H(2) blockers was 0.29 (95% confidence interval: 0.12, 0.69) and for analgesics was 0.40 (95% confidence interval: 0.22, 0.71). Results support an inverse association between occurrence of non-Hodgkin's lymphoma and use of H(2) blockers and analgesics among women, and they warrant confirmation in larger studies.

show abstract

“…Nonhematopoietic tumors that enter the differential diagnosis of T-LBL include primary or metastatic small blue round tumors to the mediastinum that vary on incidence depending on the age of the patient. In children, tumors that should be considered include Ewing sarcoma, neuroblastoma, and embryonal rhabdomyosarcoma, whereas tumors that should be considered in adults and the elderly include poorly differentiated carcinoma, small cell carcinoma, and neuroendocrine thymic carcinoma 134,135. All these tumors do not express hematopoietic-associated antigens and can be readily distinguished from T-LBL with a proper set of immunohistochemical markers, namely keratin, synaptophysin, chromogranin, FLI1, TTF1, desmin, and myogenin.…”

Section: Non-hodgkin T-cell Lymphomasmentioning

confidence: 99%

Mediastinal Lymphoproliferative Disorders

Piña‐Oviedo

2021

Advances in Anatomic Pathology

View full text Add to dashboard Cite

Lymphoproliferative disorders comprise 50% to 60% of all mediastinal malignancies in both children and adults. Primary mediastinal involvement is rare (∼5%), whereas secondary mediastinal involvement by systemic disease is more common (10% to 25%). Primary mediastinal disease is defined as involvement by a lymphoproliferative disorder of mediastinal lymph nodes, the thymus, and/or extranodal mediastinal organs without evidence of systemic disease at presentation. In this review, the clinical, radiologic, histopathologic, immunohistochemical, and genetic features of some of the most characteristic mediastinal lymphoproliferative disorders are presented. The entities discussed here include: classic Hodgkin lymphoma with emphasis on nodular sclerosis and mixed cellularity types, and non-Hodgkin lymphomas, including primary mediastinal (thymic) large B-cell lymphoma, mediastinal gray zone lymphoma, mediastinal diffuse large B-cell lymphoma, thymic marginal zone lymphoma, mediastinal plasmacytoma, T-lymphoblastic lymphoma, and anaplastic large cell lymphoma. Although not a malignant process, hyaline vascular Castleman disease is also discussed here as this disorder commonly involves the mediastinum. Despite multiple advances in hematopathology in recent decades, the day-to-day diagnosis of these lesions still requires a morphologic approach and a proper selection of immunohistochemical markers. For this reason, it is crucial for general pathologists to be familiar with these entities and their particular clinicoradiologic presentation.

show abstract

Non-Hodgkin lymphoma (NHL) as a second neoplasm occurring after neuroblastoma treatment

Cited by 7 publications

References 15 publications

Long‐term risk of second malignant neoplasms after neuroblastoma in childhood: Role of treatment

Long‐term risk of second malignant neoplasms after neuroblastoma in childhood: Role of treatment

Prescription Medications Associated with a Decreased Risk of Non-Hodgkin's Lymphoma

Mediastinal Lymphoproliferative Disorders

Contact Info

Product

Resources

About